Search

Displaying results 5161 - 5170 of 7452 in total
  1. Drug

    Sulfamazone

    go.drugbank.com/drugs/DB13556
    Experimental

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    TAK-611

    go.drugbank.com/drugs/DB17644
    Investigational

    First developed by Takeda, it is being investigated for the treatment of metachromatic leukodystrophy.

  3. Drug

    Levotofisopam

    go.drugbank.com/drugs/DB19073
    Investigational

    Levotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).

  4. Drug

    Dydrogesterone

    go.drugbank.com/drugs/DB00378
    ApprovedInvestigationalWithdrawn

    A synthetic progestational hormone with no androgenic or estrogenic properties.

  5. Drug

    1,4-Dithiothreitol

    go.drugbank.com/drugs/DB04447
    Experimental

    A reagent commonly used in biochemical studies as a protective agent to prevent the oxidation of SH (thiol) groups and for reducing disulphides to dithiols. [PubChem]

  6. Drug

    Metocurine

    go.drugbank.com/drugs/DB01336
    Approved

    Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant.

  7. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding.

  8. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.

    Categories: Corticosteroids for Systemic Use
  9. Drug

    Tolazamide

    go.drugbank.com/drugs/DB00839
    Approved

    A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.

  10. Drug

    TSHA-118

    go.drugbank.com/drugs/DB16996
    Experimental

    TSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.